IBB - iShares Nasdaq Biotechnology ETF

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
104.96
-0.93 (-0.88%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close105.89
Open105.74
Bid104.43 x 900
Ask105.22 x 100
Day's Range104.69 - 106.09
52 Week Range94.20 - 119.30
Volume1,682,654
Avg. Volume3,075,152
Net Assets9.03B
NAV106.73
PE Ratio (TTM)3.65
Yield0.21%
YTD Return-0.03%
Beta (3y)1.40
Expense Ratio (net)0.47%
Inception Date2001-02-05
Trade prices are not sourced from all markets
  • Stock Market Analysis 4/18/18
    Yahoo Finance Contributors2 days ago

    Stock Market Analysis 4/18/18

  • Yahoo Finance Contributors7 days ago

    Stock Market Video Analysis 4/14/19

  • Stock Market, Gold & Bitcoin Analysis 4/6/18
    Yahoo Finance Contributors14 days ago

    Stock Market, Gold & Bitcoin Analysis 4/6/18

  • Stock Market, Bitcoin & Gold Analysis March 9, 2018
    Yahoo Finance Contributorslast month

    Stock Market, Bitcoin & Gold Analysis March 9, 2018

  • What strong global growth means for US markets
    CNBC Videos4 days ago

    What strong global growth means for US markets

    Kevin Mahn, Hennion and Walsh Asset Management, and Sorin Roibu, Brandywine Global, discuss the IMF's 3 percent growth forecast and what to expect this earnings season.

  • Earnings bar too high? Experts weigh in
    CNBC Videos8 days ago

    Earnings bar too high? Experts weigh in

    Chris Zaccarelli, Independent Advisor Alliance, and Dan Wantrobski, Janney Montgomery Scott, discuss whether the market's response to bank earnings is indicative of things to come.

  • Cramer Remix: Here's how Mark Zuckerberg should respond t...
    CNBC Videoslast month

    Cramer Remix: Here's how Mark Zuckerberg should respond t...

    Jim Cramer explains why Facebook’s current approach isn’t working and how the company should proceed.

  • Cramer: These charts show 'signs of life' for biotech
    CNBC Videoslast month

    Cramer: These charts show 'signs of life' for biotech

    Jim Cramer eyes the biotechnology sector with technician Carolyn Boroden so see if the troubled stock group can bounce back anytime soon.

  • Cramer's charts show 'signs of life' for the struggling b...
    CNBC Videoslast month

    Cramer's charts show 'signs of life' for the struggling b...

    Jim Cramer eyes the biotechnology sector with technician Carolyn Boroden so see if the troubled stock group can bounce back anytime soon.

  • Market Realist2 days ago

    No Bid Coming for Shire Reportedly

    CNBC saying no bid is likely.  Allergan is off its lows – only down $5 now and Shire is back to flat after being up as much as $15 (~10%) earlier.

  • ETF Database2 days ago

    Trending: Investors Apathetic to Barclays' $1.2 Billion ETN Shutoff

    This week, investors were preoccupied with Russia, as the country’s equities fell dramatically after the relations with countries in the West, including the U.S., deteriorated. First in the list, however, is Barclays Capital, as the asset management arm of the British bank said it would shut down a host of exchange-traded notes (ETNs). Russia is second in the list followed by crude oil, which has been on a tear lately thanks to dropping stockpiles in the U.S. Leveraged ETFs and biotechnology stocks close the list. Check our previous trends edition at Trending: Soybean Prices Whipsaw on Trade War Fears.

  • Why These Small Cap Biotech ETFs are Soaring
    Zacks2 days ago

    Why These Small Cap Biotech ETFs are Soaring

    These biotech ETFs have surged this year thanks mainly to tax reform, rising M&A and positive regulatory backdrop.

  • Investopedia9 days ago

    3 Biotech Stocks Analysts Have Been Too Bullish On

    Regeneron, Incyte and Tesaro have all had a terrible start to 2018, with shares down 14% or more.

  • InvestorPlace12 days ago

    Exact Sciences Corporation Could Break Out Despite Steep Drop in Biotech

    EXAS stock is down almost 29% in the same period. Exact is a promising laboratory and research firm in the business of screening patients for colon cancer. Patient compliance for the screening test is at a modest 65% .

  • Investopedia14 days ago

    Biotech's Exact Sciences Seen Plunging 25%

    With shares around $38.75, options traders are betting the stock falls by another 25% by Dec. 31.

  • Market Realist15 days ago

    Can You Avoid the Tariff Trouble in the S&P 500?

    The market did kind of decide to shrug off tariffs and hope they were more of a bargaining chip. If we shrug off the tariffs today, that would be a big win for the market. When they move up, the market worries about choking off growth.

  • Barrons.com17 days ago

    Biotech Sector Could See New Life

    Biotech hasn't had a great start to the year: The iShares Nasdaq Biotechnology ETF (IBB) is down 4.4% year-to-date, and while the SPDR S&P Biotech ETF (XBI) has been the better performer of the two, as Barron's predicted, it's fallen 1.4%.  However, Oppenheimer's Leah Rush Cann thinks that the group could be poised for a positive reversal, based on valuation--which she believes looks attractive--along with earnings growth expectations. Cann writes that she has long held that the biggest catalyst for biotech stocks is the increase expectations for earnings for 2019, and now that that's finally happened, she's more optimistic about the stocks. The Street now expects biotech's earnings growth will exceed the S&P 500's by 20 basis points, a reversal from the pat two years, when biotechs were expected to lag the index.

  • ETF Trends18 days ago

    Alkermes FDA Refusal: Biotech ETFs Dragged Down

    Biotechnology stocks and biotech ETFs were among the worst performing areas of the markets Monday as Alkermes (NasdaqGS: ALKS) shares plunged after the U.S. food and Drug Administration refused to review ...

  • Market Realist19 days ago

    A New Month for Stocks, but the Same Problems

    A New Month for Stocks, but the Same ProblemsApril coming in like a lion

  • A Look at Ionis’s Key Revenue Drivers in 4Q17
    Market Realist26 days ago

    A Look at Ionis’s Key Revenue Drivers in 4Q17

    How Ionis Pharmaceuticals Is Positioned in 2018

  • Incyte’s Jakafi in 2017
    Market Realist26 days ago

    Incyte’s Jakafi in 2017

    Who’s Watching Incyte Corporation in March 2018?

  • The 4 Top Biotech ETFs
    Motley Foollast month

    The 4 Top Biotech ETFs

    Investing in biotechnology has been very lucrative lately, and these funds can help you tap into the industry's success.

  • Here's an ETF to Invest in Immunotherapy--the Game Changing Cancer Treatment
    Zackslast month

    Here's an ETF to Invest in Immunotherapy--the Game Changing Cancer Treatment

    CNCR ETF is up about 30% this year; here is what investors need to know about immunotherapy and the ETF (CNCR, IBB).

  • Investopedialast month

    3 Hot Junior Biotech Plays

    These three small-cap biotech stocks are attracting significant buying interest in this mixed March environment.

  • bluebird bio Inc (BLUE), Iqvia Holdings Inc (IQV): Four Biotech Stocks to Buy Now
    Insider Monkeylast month

    bluebird bio Inc (BLUE), Iqvia Holdings Inc (IQV): Four Biotech Stocks to Buy Now

    Healthcare sector has proven itself to be one of the most resilient sectors of the US economy. Since healthcare cannot be outsourced and represents an expense that people usually cut on last during economic downturns, investing in healthcare stocks is a good way to recession-proof your portfolio. Moreover, the sector itself is comprised of many […]